Benzinga’s Top Ratings Upgrades, Downgrades For June 13, 2023
Upgrades According to Goldman Sachs, the prior rating for Oracle Corp (NYSE:ORCL) was changed from Sell to Neutral.…
Editas’ Gene Editing Treatment Shows Initial Safety, Efficacy In Patients With Rare Blood Disorders
Editas Medicine Inc (NASDAQ: EDIT) annou
Editas Medicine’s Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Editas Medicine (NASDAQ:EDIT) posted sales of $9.85 million. Earnings were up…
ONEOK, PacWest Bancorp And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Editas Medicine To Present Clinical Data From The RUBY Trial Of EDIT-301 For The Treatment Of Severe Sickle Cell Disease At The EHA 2023 Congress
Editas Medicine, Inc. (NASDAQ:EDIT), a clinical stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the Phase 1/2 RUBY trial of EDIT-301 in
6 Analysts Have This to Say About Editas Medicine
Analysts have provided the following ratings for Editas Medicine (NASDAQ:EDIT) within the last quarter: Bullish Somewhat Bullish Indifferent…
Editas Medicine: Q1 Earnings Insights
Editas Medicine (NASDAQ:EDIT) reported its Q1 earnings results on Friday, May 5, 2023 at 07:00 AM. Here’s what…
Earnings Scheduled For May 5, 2023
Companies Reporting Before The Bell
• CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion.
Preview: Editas Medicine’s Earnings
Editas Medicine (NASDAQ:EDIT) is set to give its latest quarterly earnings report on Friday, 2023-05-05. Here’s what investors…
Editas Medicine Announces Publication In Nature Biotechnology Of Comprehensive SLEEK Gene Editing Technology Data
Editas Medicine, Inc. (NASDAQ:EDIT), a clinical stage genome editing company, today announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK